CD10
Aliases: | CALLA, CD10, CMT2T, NEP, SCA43, SFE |
---|---|
Other: | neprilysin|atriopeptidase|common acute lymphocytic leukemia antigen|membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, CALLA, CD10)|membrane metallo-endopeptidase variant 1|membrane metallo-endopeptidase variant 2|neprilysin-390|neprilysin-411|neutral endopeptidase 24.11|skin fibroblast elastase |
The protein encoded by this gene is a type II transmembrane glycoprotein and a common acute lymphocytic leukemia antigen that is an important cell surface marker in the diagnosis of human acute lymphocytic leukemia (ALL). The encoded protein is present on leukemic cells of pre-B phenotype, which represent 85% of cases of ALL. This protein is not restricted to leukemic cells, however, and is fou... see more
Brilliant Ultraviolet 737
Common Laser: | 355 |
---|---|
Common Filter: | 740/35 |
Excitation Peak: | 348 |
Emission Peak: | 737 |
Brilliant™ UltraViolet 737 (BUV737) is a near infrared-emitting tandem fluorophore that combines BD Horizon® BUV395 and an acceptor dye. It can be excited by the 355 nm ultraViolet laser and collected using a 740/35 bandpass filter. BUV737 has an excitation peak at 498 nm and an emission peak at 732 nm BUV737 has a medium/high relative brightness, and is most commonly used for multicolor flow ... see more
Popular CD10 Brilliant Ultraviolet 737 Antibodies
Company / SKU |
Applications | Marker / Reactivity |
Host / Isotype / Clone |
Size / Price |
Details | |
---|---|---|---|---|---|---|
BD Biosciences 612826 |
FC | CD10 Human,Baboon,Cynomolgus,Rhesus |
Mouse IgG1 κ HI10a |
100 Tests $407 |
Details | |
BD Biosciences 748306 |
FC | CD10 Human |
Mouse IgG2a κ W8E7 |
50 μg $495 |
Details | |
BD Biosciences 741825 |
FC | CD10 Human |
Mouse IgG1 κ HI10a |
50 μg $495 |
Details | |
BD Biosciences 564959 |
FC | CD10 Human |
Mouse IgG1 κ HI10a |
100 Tests $395 |
Details | |
BD Biosciences 748730 |
FC | CD10 Human |
Mouse IgG1 κ MEM-78 |
50 μg $495 |
Details | |
Browse CD10 / Brilliant Ultraviolet 737 antibodies. |